{Reference Type}: Journal Article
{Title}: Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present).
{Author}: Kosar M;Mach L;Carreira EM;Nazaré M;Pacher P;Grether U;
{Journal}: Expert Opin Ther Pat
{Volume}: 34
{Issue}: 8
{Year}: 2024 Aug 2
{Factor}: 6.714
{DOI}: 10.1080/13543776.2024.2368745
{Abstract}: <B>UNASSIGNED: </B>Cannabinoid receptor type 2 (CB2R), predominantly expressed in immune tissues, is believed to play a crucial role within the body's protective mechanisms. Its modulation holds immense therapeutic promise for addressing a wide spectrum of dysbiotic conditions, including cardiovascular, gastrointestinal, liver, kidney, neurodegenerative, psychiatric, bone, skin, and autoimmune diseases, as well as lung disorders, cancer, and pain management.<BR><B>UNASSIGNED: </B>This review is an account of patents from 2016 up to 2023 which describes novel CB2R ligands, therapeutic applications, synthesis, as well as formulations of CB2R modulators.<BR><B>UNASSIGNED: </B>The patents cover a vast, structurally diverse chemical space. The focus of CB2R ligand development has shifted from unselective dual-cannabinoid receptor type 1 (CB1R) and 2 agonists toward agonists with high selectivity over CB1R, particularly for indications associated with inflammation and tissue injury. Currently, there are at least eight CB2R agonists and one antagonist in active clinical development. A better understanding of the endocannabinoid system (ECS) and in particular of CB2R pharmacology is required to unlock the receptor's full therapeutic potential.